Product Details
| Product Name:
Paquinimod |
CAS No.:
248282-01-1 |
| Purity:
99.79% |
Supply Ability:
10g |
| Release date:
2024/11/08 |
Product Introduction
Bioactivity
| 名稱 | Paquinimod |
| 描述 | Paquinimod (ABR 25757) is a S100A9 inhibitor preventing S100A9 binding to TLR-4. |
| 動(dòng)物實(shí)驗(yàn) | Two OA mouse models differing in level of synovial activation were treated prophylactic with paquinimod. Synovial thickening, osteophyte size and cartilage damage were measured histologically, using an arbitrary score, adapted Pritzker OARSI score or imaging software, respectively. Human OA synovia were stimulated with S100A9, with or without paquinimod[1].Seven weeks old female B6.Cg-Fbn1(Tsk)/J (Tsk-1) mice were treated with vehicle or paquinimod at the dose of 5 or 25mg/kg/day in the drinking water for 8 weeks. The effect of paquinimod on the level of skin fibrosis and on different subpopulations within the myeloid cell compartment in skin biopsies were evaluated by using histology, immunohistochemisty, a hydroxyproline assay and real-time PCR. Furthermore, the level of IgG in serum from treated animals was also analysed. The statistical analyses were performed using Mann-Whitney nonparametric two tailed rank test[1]. |
| 體內(nèi)活性 | Prophylactic treatment of paquinimod reduces synovial activation, osteophyte formation and cartilage damage in experimental OA with high synovial activation (CIOA) and ameliorates pathological effects of S100A9 in OA synovium ex vivo[1].Treatment with paquinimod reduces skin fibrosis measured as reduction of skin thickness and decreased number of myofibroblasts and total hydroxyproline content. The effect on fibrosis was associated with a polarization of macrophages in the skin from a pro-fibrotic M2 to a M1 phenotype. Paquinimod treatment also resulted in a reduced TGFβ-response in the skin and an abrogation of the increased auto-antibody production in this SSc model[1]. |
| 存儲(chǔ)條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| 溶解度 | DMSO : 50 mg/mL (142.69 mM)
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 12.5 mg/mL (35.67 mM), Suspension. Please add co-solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately.
|
| 關(guān)鍵字 | Inhibitor | inhibit | ABR25757 | ABR-25757 | Paquinimod |
| 相關(guān)庫(kù) | 經(jīng)典已知活性庫(kù) | ReFRAME 相關(guān)化合物庫(kù) | 藥物功能重定位化合物庫(kù) | 抗病毒庫(kù) | 抑制劑庫(kù) | NO PAINS 化合物庫(kù) | 臨床期小分子藥物庫(kù) | 已知活性化合物庫(kù) | 人代謝物化合物庫(kù) |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:33419-42-0
$108.00 / 500mg
-
CAS:747412-49-3
$52.00 / 5mg
-
CAS:90417-38-2
$39.00 / 5mg
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$/ |
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |
United States